Immatics N.V. (IMTX) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 12.65
30Y Low12.7·High12.7
P/FCF
N/A
—
5yr avg: 6.38
30Y Low6.4·High30.6
P/B Ratio
↓
1.76
↓-82% vs avg
5yr avg: 9.60
30Y Low1.3·High35.1
ROE
↑
3.8%
↓+102% vs avg
5yr avg: -176.1%
30Y Low-148%·High32%
Debt/EBITDA
N/A
—
5yr avg: 0.40
30Y Low0.4·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immatics N.V. trades at 67.8x earnings, 103% above its 5-year average of 33.5x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 204%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $759M | $848M | $599M | $846M | $518M | $654M | $617M |
| Enterprise Value | $1.2B | $539M | $645M | $466M | $722M | $317M | $554M | $577M |
| P/E Ratio → | 67.81 | 50.79 | — | 16.13 | — | — | — | — |
| P/S Ratio | 8.17 | 4.87 | 15.71 | 3.47 | 24.32 | 16.57 | 35.46 | 163.53 |
| P/B Ratio | 1.76 | 1.32 | 3.77 | 2.81 | 35.14 | 4.97 | — | — |
| P/FCF | — | — | — | 6.38 | — | — | 9.52 | 30.55 |
| P/OCF | — | — | 46.53 | 5.99 | — | — | 9.22 | 29.81 |
P/E links to full P/E history page with 30-year chart
IMTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.46 | 11.95 | 2.69 | 20.78 | 10.13 | 30.04 | 153.09 |
| EV / EBITDA | — | — | — | 12.65 | — | — | — | — |
| EV / EBIT | — | 24.23 | — | 10.81 | — | — | — | — |
| EV / FCF | — | — | — | 4.96 | — | — | 8.06 | 28.60 |
IMTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Immatics N.V. earns an operating margin of -24.8%. Operating margins have compressed from 17.3% to -24.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 3.8% is modest.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -119.8% | 38.2% | -151.9% | -114.7% | -117.3% | -801.1% |
| Operating Margin | -24.8% | -24.8% | -188.4% | 17.3% | -248.2% | -223.1% | -178.9% | -912.7% |
| Net Profit Margin | 9.8% | 9.8% | -179.6% | 21.7% | -273.5% | -733.8% | -172.0% | -834.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | 3.8% | 3.8% | -44.3% | 31.6% | -148.2% | -723.3% | — | — |
| ROA | 2.5% | 2.5% | -21.1% | 12.9% | -44.3% | -117.9% | -32.5% | -51.3% |
| ROIC | -15.4% | -15.4% | -150.7% | 28.4% | — | — | — | — |
| ROCE | -7.9% | -7.9% | -31.1% | 15.7% | -63.1% | -53.8% | -66.4% | -99.8% |
IMTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $237M exceeds total debt of $16M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.07 | 0.07 | 0.41 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | 0.40 | — | — | — | — |
| Net Debt / Equity | — | -0.38 | -0.90 | -0.63 | -5.12 | -1.93 | — | — |
| Net Debt / EBITDA | — | — | — | -3.64 | — | — | — | — |
| Debt / FCF | — | — | — | -1.43 | — | — | -1.46 | -1.95 |
| Interest Coverage | -43.58 | -43.58 | -122.41 | 28.86 | -152.46 | -241.23 | -194.19 | -2150.56 |
Net cash position: cash ($237M) exceeds total debt ($16M)
IMTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Immatics N.V.'s current ratio of 9.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.54x to 9.26x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.26 | 9.26 | 2.87 | 3.54 | 1.60 | 3.94 | 1.79 | 2.06 |
| Quick Ratio | 9.26 | 9.26 | 2.87 | 3.54 | 1.60 | 3.89 | 1.77 | 2.06 |
| Cash Ratio | 8.89 | 8.89 | 2.72 | 3.40 | 1.53 | 3.83 | 1.72 | 1.95 |
| Asset Turnover | — | 0.22 | 0.11 | 0.42 | 0.20 | 0.12 | 0.14 | 0.06 |
| Inventory Turnover | 20.31 | — | — | — | — | 20.31 | 32.44 | — |
| Days Sales Outstanding | — | 15.80 | 38.78 | 2.35 | 24.77 | 34.14 | 53.87 | 176.01 |
IMTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immatics N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.5% | 2.0% | — | 6.2% | — | — | — | — |
| FCF Yield | — | — | — | 15.7% | — | — | 10.5% | 3.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $107M | $81M | $69M | $63M | $48M | $63M | $63M |
Peer Comparison
Compare IMTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMTXYou | $1B | 67.8 | — | — | 100.0% | -24.8% | 3.8% | -15.4% | — |
 TCRT | $6M | -0.9 | — | — | 100.0% | -48120.0% | -111.8% | -593.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 NKTX | $223M | -2.0 | — | — | — | — | -31.9% | -24.3% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See IMTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMTX vs TCRT
Side-by-side business, growth, and profitability comparison vs Alaunos Therapeutics, Inc..
Start ComparisonIMTX — Frequently Asked Questions
Quick answers to the most common questions about buying IMTX stock.
What is Immatics N.V.'s P/E ratio?
Immatics N.V.'s current P/E ratio is 67.8x. The historical average is 33.5x. This places it at the 100th percentile of its historical range.
What is Immatics N.V.'s ROE?
Immatics N.V.'s return on equity (ROE) is 3.8%. The historical average is -39.2%.
Is IMTX stock overvalued?
Based on historical data, Immatics N.V. is trading at a P/E of 67.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Immatics N.V.'s profit margins?
Immatics N.V. has 100.0% gross margin and -24.8% operating margin.